Our location in the heart of San Diego’s thriving life sciences community means our team is made up of industry-leading experts in a range of disciplines and from a variety of backgrounds, united by a shared passion for turning science into meaningful discoveries for cancer patients.
The power to stop cancer.
The experience to know how.
The dedication to make a difference.
Dual purpose enabling a targeted medicine approach
Part of a treatment strategy known as theragnostics, radiopharmaceuticals can be used for both therapy and diagnosis.
Radiopharmaceuticals, when tethering a radionuclide suitable for imaging, create a map of cancerous tumors in the body that provides precise diagnostic information. From the imaging results, the patients who are most likely to respond are identified and treated with individualized regiments of the therapeutic version of the same radiopharmaceutical. This precision medicine approach seeks to make substantial improvements in clinical outcomes.
Approach
Small molecules, tethered with powerful radioisotopes, are designed to exquisitely bind to receptors overexpressed in cancer and deliver powerful radiation to kill tumors, without affecting normal tissue.
Our unique approach marries a vast knowledge of GPCR biology with unrivaled proficiency in small molecule medicinal chemistry to develop potent and highly selective radiopharmaceuticals. We take a fit-for-purpose approach, pinpointing the precise target and selecting the ideal small molecule ligand paired with the optimal radioisotope to achieve a therapeutic effect.
Novel targets for solid tumors
Largest gene family in humans
132 known protein/receptor pairs
>65 with increased tumor expression
Given GPCR overexpression in many tumors, they can be targeted in a vast range of cancer indications, from common to rare tumors.
Clinical trials
Study R8760-101 is a multi-center Phase 1 clinical trial evaluating the safety and dosimetry of 68Ga-R8760, a first-in-class small molecule radioligand imaging agent being developed for patients diagnosed with adrenocortical carcinoma. 68Ga-R8760 was discovered by Radionetics Oncology for identifying melanocortin 2 receptor (MC2R)-expressing adrenocortical cancer lesions to select patients who may benefit from MC2R-directed radioconjugate therapy.
For additional information about the study, please see study NCT05999292
Meet
our team
Investors
Board
of
directors
Crinetics
Frazier Life Sciences
5AM Ventures
Boundless Bio
DCVC Bio
Radionetics Oncology
Careers
join us
News
Istvan Molnar, M.D.
Istvan Molnar, M.D. serves as Chief Medical Officer, bringing 15 years of oncology clinical development experience, including significant expertise in radiopharmaceutical clinical development. Prior to joining Radionetics, he was Chief Medical Officer at Lantheus Medical Imaging and at Fusion Pharmaceuticals. Previous to these appointments, Dr. Molnar was Vice President of Clinical Development at Merrimack Pharmaceuticals and Director and Global Clinical Lead at Bayer Pharmaceuticals. He has accumulated considerable experience in all stages of oncology drug development, encompassing several successful drug approvals with significant time spent on radiopharmaceutical projects at Bayer, Fusion Pharmaceuticals and Lantheus Medical Imaging including radium-223 dichloride (Xofigo®) and piflufolastat F 18 (Pylarify®) for prostate cancer. Prior to his industry career, he was Assistant Professor at Wake Forest University. Dr. Molnar obtained his medical degree at Semmelweis University in Budapest, Hungary and completed an internal medicine residency at Meridia Huron Hospital in Ohio and a Hematology-Oncology Fellowship at Wake Forest University School of Medicine in North Carolina.